

KRONOLOGIS KORESPONDENSI PUBLIKASI JURNAL

Judul : Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study

Jurnal : F1000Research

Author : **Anggraini Dwi Sensusiati**, Muhammad Amin, Nasronudin Nasronudin, Alfian Nur Rosyid, Nanda Aulya Ramadhan, Rofida Lathifah, Eva Puspitasari, Ria Indah Wahyuningtyas, Erika Soebakti

First Author : **Anggraini Dwi Sensusiati**

Corresponding Author : **Anggraini Dwi Sensusiati**

Kronologis Korespondensi Publikasi Jurnal

No	Tanggal	Status Publikasi
1.	10 September 2020	Artikel berhasil tersubmit di F1000Research
2.	23 September 2020	Email dari F1000 Research: Naskah Diterima Bersyarat di F1000Research. Diperlukan revisi.
3.	1 Oktober 2020	Pengiriman manuskrip yang telah dirubah sesuai dengan arahan email dari F1000Research pada 23 September 2020.
4.	6 Oktober 2020	Balasan email dari F1000Research : Diperlukan pernyataan “ethical approval”
5.	6 Oktober 2020	Pengiriman manuskrip yang telah ditambahkan “ethical approval”
6	8 Oktober 2020	Email dari F1000Research: Manuskrip diterima untuk diproses oleh F1000Research
7	12 Oktober 2020	Email dari F1000Research: Permintaan saran peer reviewers
8	19 Oktober 2020	Email dari F1000Research : Diperlukan bukti perbaikan
9	25 Oktober 2020	Pengiriman bukti perbaikan

No	Tanggal	Status Publikasi
10	20 November 2020	Email dari F1000Research: Hasil peer review pertama
11	20 November 2020	Email dari F1000Research: Hasil peer review telah terbit – artikel belum lolos peer review.
12	21 Desember 2020	Email dari F1000Research: Submit artikel versi terbaru telah diterima
13	4 Januari 2021	Email dari F1000Research: Artikel dengan versi terbaru dapat dipublikasikan di Jurnal F1000Research
14	5 Januari 2021	Email dari tim editor F1000Research melakukan pengecekan terakhir pada artikel
15	6 Januari 2021	Artikel berhasil diterima untuk publish di Jurnal F1000Research

Article submission received

research@f1000.com <research@f1000.com>

Thu, Sep 10, 2020 at 9:48 AM

To: anggrainids.unair@gmail.com

Dear Anggraini Dwi

Thank you for submitting your manuscript:

Age, NLR and RALE Score to predict in-hospital mortality in COVID-19 patients: a retrospective studyAnggraini Dwi Sensusiati *et al.***Funders:** no grant funding was stated during submission.**PLEASE NOTE:** due to an increase in submissions regarding COVID-19, it may take longer for us to respond to your initial submission. Please accept our apologies, and rest assured our editorial team will be in touch as soon as possible.**WHAT WE DO NEXT****Before accepting your article:** we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).**Before publishing your article:** if we accept your article, we will be in touch as soon as possible with any issues that need addressing. You will then receive a final proof of your article for approval, prior to publication.**WHAT YOU NEED TO DO NEXT**Before doing anything else, we need you to suggest **at least 5** suitable reviewers to peer review your manuscript following publication (in accordance with our [publishing model](#)), should it be accepted. We ask that authors do not contact reviewers directly about the peer review process. We will need your reviewer suggestions before we can publish the article so we recommend identifying them now via your [Suggest Reviewers](#) page for this article. You can also access this page via the article's record at [My Research >> Submissions](#).

Please quote the article number 26723 in any correspondence.

Kind regards

The F1000Research Team

Press releasing articles: Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER29506-A (end code)

Manuscript 26723 conditionally accepted for publication

research@f1000.com <research@f1000.com>

Wed, Sep 23, 2020 at 12:40 PM

To: anggrainids.unair@gmail.com

Dear Anggraini Dwi

Age, NLR and RALE Score to predict in-hospital mortality in COVID-19 patients: a retrospective study
Sensusiati AD, Amin M, Nasronudin N, Rosyid AN, Ramadhan NA, Lathifah R, Puspitasari E, Wahyuningtyas RI *et al.*

Thank you for your submission to F1000Research. We have noted a few issues with your manuscript (below) – once these are addressed we will be pleased to accept your article for publication.

Content: We endorse the [STROBE statement](#) for observational cross-sectional reporting. We would suggest that you check that the article adheres to this checklist; Track changes in the Word document provide some queries relating to the STROBE checklist, but these are not exhaustive.

Data availability: Thank you for providing your underlying data. Please provide a key so that that data can be interpreted by others.

We ask that authors submit their underlying data to an online repository. More information can be found on [our data guidelines page](#). When submitting data to an online repository, please ensure you create a DOI, which will be stated and cited in the Data availability section of the manuscript. Please include the name of the repository and the DOI in the Data availability section, along with the license the data is held under (please make sure that you choose a license when submitting your data to a repository – we would strongly suggest a CC0 license).

If you are submitting data to Open Science Framework, please register your project to ensure that a record of this project will remain persistent and unchangeable (an open-ended registration is usually the most appropriate). Once you have registered your project, please create a DOI for this registration by clicking the pencil icon next to 'Registration DOI'. This DOI will be stated and cited in the Data availability section of the manuscript.

To ensure you and your co-authors receive appropriate credit for generating your datasets, please ensure you include the names of all authors involved in producing the data. To maximise the likelihood of your data being cited correctly, we strongly encourage you to link the ORCIDs of every author involved in generating the data, where possible.

Please make sure that data is deidentified prior to uploading according to the Safe Harbour method.

Reviewers: Thank you for providing 4 reviewers for the post-publication peer review process; our peer review team will check these suggestions and be in contact presently.

Payment: As F1000Research is open access, we will require payment of the Article Processing Charge (APC) to be able to complete the processing of your submission. The APC is \$1350.00 after any discounts you are eligible for have been applied. **Please provide us with the details of the individual/organization taking responsibility for paying the fee as soon as possible.** Please sign in with the credentials you used to submit the article or you will not be able to access this page. Our Accounts department will be in touch regarding payment.

We have also lightly copyedited your article - please [download the document](#) and check you are happy with the amendments and **then address the queries detailed above using track changes in Word. Please return your revised manuscript to the e-mail address above.** Please note that this is your final opportunity to make any changes to the content of your manuscript. Once the typeset PDF of your manuscript has been created, we will send you a final PDF proof for checking prior to publication.

Best wishes,

Molly
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER29506-A (end code)

Manuscript 26723 conditionally accepted for publication

Anggraini Dwi Sensusiati <anggrainids.unair@gmail.com>

Thu, Oct 1, 2020 at 4:55 PM

To: research@f1000.com

Dear Molly,

Thank you for giving us the opportunity to publish in F1000Research. Attached below is the amended manuscript. Please let us know if there's anything else that we need to do.

Best wishes

Anggraini Dwi

[Quoted text hidden]



f1000research-null-null-v1 edited.docx

73K

Manuscript 26723 conditionally accepted for publication

F1000.Research <research@f1000.com>

Tue, Oct 6, 2020 at 10:47 AM

To: Anggraini Dwi Sensusiati <anggrainids.unair@gmail.com>

Dear Anggraini Dwi

Thank you for returning your revisions so promptly. There is just one remaining query before I send your article to be typeset:

We noticed that you do not have a statement about ethical approval for the study. Please confirm that you received approval for this study, and include a statement in the manuscript that details the approval committee name and the approval number, if applicable. In addition, please provide a statement about consent from the participants, if this was waived by the committee, please state this. Please see our policies for more information.

Best regards,

Molly

Molly Cranston
Editorial LeadF1000 Research Ltd | Email: molly.cranston@f1000.comMaple House, [147 Tottenham Court Road, London, W1T 7NF](#)

[Quoted text hidden]

[Quoted text hidden]

Dear Anggraini Dwi

Age, NLR and RALE Score to predict in-hospital mortality in COVID-19 patients: a retrospective study
Sensusiati AD, Amin M, Nasronudin N, Rosyid AN, Ramadhan NA, Lathifah R, Puspitasari E, Wahyuningtyas RI *et al.*

Thank you for your submission to F1000Research. We have noted a few issues with your manuscript (below) – once these are addressed we will be pleased to accept your article for publication.

Content: We endorse the [STROBE statement](#) for observational cross-sectional reporting. We would suggest that you check that the article adheres to this checklist; Track changes in the Word document provide some queries relating to the STROBE checklist, but these are not exhaustive.

Data availability: Thank you for providing your underlying data. Please provide a key so that that data can be interpreted by others.

We ask that authors submit their underlying data to an online repository. More information can be found on [our data guidelines page](#). When submitting data to an online repository, please ensure you create a DOI, which will be stated and cited in the Data availability section of the manuscript. Please include the name of the repository and the DOI in the Data availability section, along with the license the data is held under (please make sure that you choose a license when submitting your data to a repository – we would strongly suggest a CC0 license).

If you are submitting data to Open Science Framework, please register your project to ensure that a record of this project will remain persistent and unchangeable (an open-ended registration is usually the most appropriate). Once you have registered your project, please create a DOI for this registration by clicking the pencil icon next to 'Registration DOI'. This DOI will be stated and cited in the Data availability section of the manuscript.

To ensure you and your co-authors receive appropriate credit for generating your datasets, please ensure you include the names of all authors involved in producing the data. To maximise the likelihood of your data being cited correctly, we strongly encourage you to link the ORCIDs of every author involved in generating the data, where possible.

Please make sure that data is deidentified prior to uploading according to the Safe Harbour method.

Reviewers: Thank you for providing 4 reviewers for the post-publication peer review process; our peer review team will check these suggestions and be in contact presently.

Payment: As F1000Research is open access, we will require payment of the Article Processing Charge (APC) to be able to complete the processing of your submission. The APC is \$1350.00 after any discounts you are eligible for have been applied. **Please provide us with the details of the individual/organization taking responsibility for paying the fee as soon as possible.** Please sign in with the credentials you used to submit the article or you will not be able to access this page. Our Accounts department will be in touch regarding payment.

We have also lightly copyedited your article - please [download the document](#) and check you are happy with the amendments and **then address the queries detailed above using track changes in Word. Please return your revised manuscript to the e-mail address above.** Please note that this is your final opportunity to make any changes to the content of your manuscript. Once the typeset PDF of your manuscript has been created, we will send you a final PDF proof for checking prior to publication.

Best wishes,

Molly
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER29506-A (end code)

[Information Classification: General](#)

Manuscript 26723 conditionally accepted for publication

Anggraini Dwi Sensusiati <anggrainids.unair@gmail.com>

Tue, Oct 6, 2020 at 2:16 PM

To: "F1000.Research" <research@f1000.com>

Deal Molly,

The study received ethical approval from the Ethical Committee of Airlangga University Teaching Hospital. Attached below is the manuscript with the ethical approval statement.

Thank you very much for your assistance.

Best wishes,

Anggraini Dwi

[Quoted text hidden]

**f1000research-null-null-v1 edited.docx**

73K

Your article 26723 is now accepted

research@f1000.com <research@f1000.com>

Thu, Oct 8, 2020 at 6:28 AM

To: anggrainids.unair@gmail.com

Dear Anggraini Dwi

Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study

Sensusiaty AD, Amin M, Nasronudin N, Rosyid AN, Ramadhan NA, Lathifah R, Puspitasari E, Wahyuningtyas RI *et al.*

PLEASE NOTE: due to an increase in submissions regarding COVID-19, it may take longer for us to send you a PDF proof of your article. Please accept our apologies, and rest assured our editorial team will be in touch as soon as possible.

We have now accepted your article for publication in F1000Research. It will be sent to the typesetters and a member of the Production team will send you a proof in due course.

One of our editorial team will be assisting you with the peer review process of your article, and will be your main contact once the article is published.

Best wishes,

Molly

The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER29506-A (end code)

Request for peer reviewer suggestions F1000Research

F1000.Research <research@f1000.com>

Mon, Oct 12, 2020 at 11:19 PM

To: "anggrainids.unair@gmail.com" <anggrainids.unair@gmail.com>

Dear Anggraini,

We have now completed the required checks to ensure your suggestion reviewers meet our reviewer criteria. Whilst several of your suggested reviewers meet our criteria, F1000Research requires a global spread of reviewers to ensure that an international perspective of the article can be gained. Please suggest a further 4 geographically-diverse reviewers, so that we can publish your article. We recommend suggesting as many names as you can, as the more names suggested the higher the chances of getting your paper reviewed. We recommend suggesting 5-10 people at a time, as the more names suggested the higher the chance someone will be available to review your article, but please continue to adhere to the reviewer criteria. Please visit your [Suggest Reviewers page](#) to add your suggestions.

Kind regards,

Lewis

The Editorial Team, F1000Research

[Information Classification: General](#)

26723 - Anggraini Dwi Sensusiati: Proof Corrections Required

production.research@f1000.com <production.research@f1000.com>

Mon, Oct 19, 2020 at 10:27 PM

To: anggrainids.unair@gmail.com

Dear Anggraini Dwi,

You should recently have received the proofs of your F1000Research article "Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study" from us.

Please mark on the PDF where references "Liu *et al.*, 2020", "Terpos *et al.*, 2020", "Wang *et al.* (2020)" & "Woldometers (2020)" should be cited in the main text- unless they can be deleted from page 7?

Please provide us with the full references for citations "Liu *et al.*, 2019" & "Wang, 2020" unless they need to be edited/deleted from the main text?

Please return your proof corrections to us via email.

If you haven't received the proof email, do let us know and we will resend it.

Kind regards

The Production Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER29506-A (end code)

26723 - Anggraini Dwi Sensusiati: Proof Corrections Required

Anggraini Dwi Sensusiati <anggrainids.unair@gmail.com>

Mon, Oct 26, 2020 at 4:59 PM

To: production.research@f1000.com

Dear Production Team of F1000Research,

Attached below is the correction of the article. I have added the comments on the PDF document. Those are some corrections:

1. Please delete the Terpos et al., 2020 reference
2. I have added the correction for Liu et al., 2020; Wang et al., 2020; and Worldometers, 2020
3. Please change the order of the author's affiliations (see comment section)
4. Please change the number of the author's affiliations (see comment section)
5. Please replace Airlangga University Teaching Hospital with Universitas Airlangga Hospital
6. On Table 4, please replace CXR Score with RALE Score

All the author names are spelled correctly.

Thank you very much for your assistance.

Regards,

Anggraini Dwi

[Quoted text hidden]

**bb998c4f-24f8-4c05-a4b9-c84fadb01a06_26723_-_anggraini_dwi_sensusiati.pdf**

1038K

First peer review report published

research@f1000.com <research@f1000.com>

Fri, Nov 20, 2020 at 6:43 PM

To: anggrainids.unair@gmail.com

Dear Anggraini

Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study

Sensusiaty AD, Amin M, Nasronudin N, Rosyid AN, Ramadhan NA, Lathifah R, Puspitasari E, Wahyuningtyas RI *et al.*

We have just published a peer review report for your article on F1000Research, which you can read [here](#).

If you wish to respond to the reviewer, please go to the link above and click 'Respond to this report' below the report. When responding to a peer review report, please try and make sure you are logged into the account that you originally used for the submission of this article, otherwise we cannot identify your response as being from an author. Please allow up to one working day for your comments to appear. If you 'Track' the article, you will automatically be alerted to any other reports or comments made.

NB: Your article will pass peer review and be indexed in PubMed, PMC, Scopus, Embase and other indexing sites, if you receive either two 'Approved' statuses, or two 'Approved with Reservations' statuses and one 'Approved' status from the reviewers.

In order to ensure that peer review proceeds quickly and you get at least one more report, we recommend that you suggest additional reviewers. Please visit [Suggest Reviewers](#), where you will find a useful tool to help you find reviewers; you can also access this page via the article's record under My Research >> Submissions. See also our [reviewer criteria and tips for finding reviewers](#).

We would recommend waiting for additional peer review reports before starting on any article revisions.

Best regards,

Lewis

The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER29506-A (end code)



Peer review report published - article has not yet passed peer review

research@f1000.com <research@f1000.com>

Fri, Nov 20, 2020 at 7:04 PM

To: anggrainids.unair@gmail.com

Dear Anggraini Dwi

Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study

Sensusiati AD, Amin M, Nasronudin N, Rosyid AN, Ramadhan NA, Lathifah R, Puspitasari E, Wahyuningtyas RI *et al.*

We have published another peer review report for your article in F1000Research at <https://f1000research.com/articles/9-1286/v1#referee-response-74043>.

You have now received 2 peer review reports. Some of your reviewers had reservations and therefore your article has not yet passed peer review, which prevents it being indexed in bibliographic databases. (*Once an article receives two 'Approved' statuses, or two 'Approved with Reservations' statuses and one 'Approved' status, it will be considered to have passed peer review.*)

Please let us know how you'd like to proceed:

1) You can revise your article and publish a new version, together with a response to the reviewers. We will then contact the reviewers again for comments on your revision and an updated approval status.

For information on how to submit a new version, please visit [Article Guidelines \(new versions\)](#). Please bear in mind that new submissions need to be created and submitted using the submitting author's account.

2) Alternatively, if you wish to continue with the peer review and try to receive further reviewers opinions before you revise, please continue to suggest additional reviewers, via your [Suggest Reviewers](#) page, where you will find a useful tool to help you find reviewers; you can also access this page via the article's record under [My Research >> Submissions](#).

It is your decision which option you wish to pursue. If we do not hear otherwise, we assume that you are revising and look forward to hearing from you when you are ready with your submission.

If you wish to respond directly to the reviewer by adding a comment to their report (now, or at a later stage), please click the 'Respond to this report' button below the report. When responding to a peer review report, please try and make sure you are logged into the account that you originally used for the submission of this article, otherwise we cannot identify your response as being from an author. Please allow up to one working day for your comment to appear (comments explaining changes in the revised version of your article are usually published at the same time as the revised version).

Best regards,

Lewis
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER29506-A (end code)

Thank you for submitting a new version of your article Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study

research@f1000.com <research@f1000.com>
To: anggrainids.unair@gmail.com

Mon, Dec 21, 2020 at 10:12 PM

Dear Anggraini Dwi

Thank you for submitting a new version of your article:

Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study

Sensusiati AD *et al.*

WHAT WE DO NEXT

We will check your submission to make sure we have all the files and information we need and will be in touch in the next two to three working days. You will receive a final proof of your article for approval, prior to publication. At that point, we usually contact the reviewers who reviewed the previous version of the article for any further comments or changes to the status they originally awarded your article.

WHAT YOU NEED TO DO NEXT

Nothing, just relax and we will be in touch shortly. Don't forget you can track the progress of your article via [My Research >> My Submissions](#).

Please bear in mind that it is possible the reviewers of your previous version might not be available to review this version. If this is the case and further reviews are required, we will be in touch to discuss the best way to proceed, which may involve asking for further reviewer suggestions.

Please quote the article number 26723 in any correspondence.

Kind regards

The F1000Research Team

Press releasing articles: Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER33024-A (end code)

New version of your article 26723

research@f1000.com <research@f1000.com>

Mon, Jan 4, 2021 at 6:58 PM

To: anggrainids.unair@gmail.com

Dear Anggraini Dwi

Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study

Sensusiaty AD, Amin M, Nasronudin N, Rosyid AN, Ramadhan NA, Lathifah R, Puspitasari E, Wahyuningtyas RI *et al.*

The new version of your F1000Research article is now ready for publication. It will be sent to the typesetters, and a member of the Production team will send you a proof in due course.

Best regards,

The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER33024-A (end code)

The PDF of your article 26723 is ready for checking

production.research@f1000.com <production.research@f1000.com>

Tue, Jan 5, 2021 at 9:25 PM

To: anggrainids.unair@gmail.com

Dear Anggraini Dwi

Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study

Sensusiati AD, Amin M, Nasronudin N, Rosyid AN, Ramadhan NA, Lathifah R, Puspitasari E, Wahyuningtyas RI *et al.*

Please click [here](#) to download the PDF proof of your F1000Research article.

Please look through the article and let me know if it requires any corrections or if you are happy for it to be published as it is. Please also confirm the following details are correct:

- All author names are spelled correctly
- Authors are listed in the correct order
- Affiliations for all authors are accurate
- The information in the Copyright section is correct
- All figures and figure legends are correct
- All external files, including data files are correct
- All links within the article are working, and correct

Please note that connecting an ORCID account to F1000Research requires the account holder to sign in to both F1000Research and ORCID, **therefore it isn't possible for us to add ORCID badges for your co-authors on their behalf**. When the article is published, they will receive an email encouraging them to connect their ORCID account to F1000Research. If they do this, their ORCID badge will be displayed next to their name.

Corrections at this stage may require further typesetting and therefore cause some delays. If any corrections are necessary, please mark them directly on the PDF file using the commenting and markup tools in software such as Adobe Reader.

Please return your proof corrections to us via email - please note that after the article has been published, any requests for minor corrections will only be considered on a case-by-case basis. Therefore, we encourage you to check your proofs carefully at this stage.

If there are any outstanding queries on your reviewer suggestions, then we will be in touch with you shortly.

Best regards,

Lois
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER33024-A (end code)

New Version of your article published on F1000Research

production.research@f1000.com <production.research@f1000.com>

Wed, Jan 6, 2021 at 6:30 PM

To: anggrainids.unair@gmail.com

Dear Anggraini Dwi,

I'm pleased to let you know that your article: "Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study" has just been [published on F1000Research](#).

The Peer Review Process

If peer review reports have previously been published on your article, we are currently in the process of re-contacting these reviewers to ask if they are available to re-review your revised article. Peer reviewers are given the opportunity to update their previously assigned Report Status and provide any additional feedback they may have. We will be in touch to let you know if and when any updated peer review reports for your article are published. If your article is still in need of additional reports, please provide additional reviewer suggestions via the [Suggest Reviewers](#) page; this page can also be accessed via the article's record at [My Research >> Submissions](#).

It is important that authors do not contact the reviewers directly, as this could result in invalidating their peer review reports.

Please note that we will ask you for additional suggestions if your original reviewers decline. In order to avoid any delays with the peer review of your article, please continue to check your [Suggest Reviewers](#) page for updates and respond to any email requests as soon as you can.

Increasing Discoverability

Now that this new version of your article has been published, you can maximize its reach by using the Email and Share options on the article page.

The ePMC record for this article has been updated to reflect the new version, and if a previous version has already passed peer review it will also be updated with the relevant indexers.

Regards

Zena Nyakoojo
Senior Managing Editor, F1000Research

Press releasing articles: Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER33024-A (end code)